IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV

FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S